At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 57 enrolled
Drug / intervention
Alprostadil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon
In Brief
A Phase 4 clinical trial evaluating Alprostadil and Nitroglycerin for ST Segment Elevation Myocardial Infarction and Coronary Slow Flow Phenomenon. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
Primary CompletionApr 2017
Study CompletionAug 2017
First PostedSep 2017
TodayJul 2026
First PostedSep 28, 2017
Enrollment StartAug 1, 2015
Primary CompletionApr 28, 2017
Study CompletionAug 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.8 years ago
Interventions
Alprostadildrug
alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Nitroglycerindrug
Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP